Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources
←Back to briefings
Comvita (CVT) / HY26

Comvita swung to $4.6m NPAT, but FCF leans on $52m inventory unwind

The operating turnaround is real, yet FCF-to-NPAT of 357.3% reflects working-capital release and a 76% capex cut rather than steady-state cash

Consumer / Honey and wellness

CVT revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY26 was $118m, versus $103.4m in HY24.

CVT Operating profit margin

Operating profit margin across covered periods.

↗
Loading chart...
HY26 was 6.5%, versus 5.9% in HY24.

CVT operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY26 was $20.8m, versus -$6.1m in HY24.

CVT working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY26 was -$50.2m, versus $148.3m in HY24.
Release date
23 February 2026
Published
21 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Analysis
  3. Chat
  4. Data
  5. Sources

Key metrics

Numbers worth scanning first

HY26 vs HY25

Revenue

$118m

+18.3% ↑ vs $99.7m

Net profit after tax

$4.6m

+170.8% ↑ vs −$6.5m

Net cash inflow from operating activities

$20.8m

+110.8% ↑ vs $9.8m

Operating profit

$7.7m

+248.1% ↑ vs −$5.2m

Profit before tax

$4.3m

+147.8% ↑ vs −$9m

Cash and cash equivalents

$10.3m

-24.5% ↓ vs $13.6m

Total assets

$164.4m

-44.3% ↓ vs $295.3m

What changed

Comvita returned to profit and de-leveraged sharply, but the cash story is dominated by a balance-sheet unwind rather than recurring cash generation

Revenue rose 18.3% to $118.0m and PBT swung to $4.3m from a $9.0m loss (+147.4%), with NPAT at $4.6m versus a $6.5m loss (+170.8%). Operating cash flow more than doubled to $20.8m and free cash flow reached $16.4m, up $14.4m.

The mechanism behind the cash result is visible on the balance sheet. Inventories fell from $120.8m to $68.3m (-43.4%), with inventory days dropping from 220 to 105. Capex was cut 75.6% to $0.5m, only 0.4% of revenue. Net debt fell to $48.7m from $81.6m, and gross borrowings dropped 38.1%. Equity is now $58.3m, 61.5% below prior comparable, reflecting the $104.8m FY25 loss that sits between these two halves.

What matters

Cash conversion is overstated by working-capital release

FCF-to-NPAT at 357.3% is not a durable conversion rate. The $14.4m year-on-year FCF uplift sits against a $52.5m inventory drawdown and a $1.5m capex cut. This means the underlying cash-generation capacity of the business at a normalised inventory level and a normalised capex profile cannot be inferred from this half.

Leverage has materially improved, and that changes financial flexibility. Net debt dropped $32.9m to $48.7m, and the leverage direction is strengthening. Combined with a smaller, simpler balance sheet (total assets -44.3%), Comvita has bought itself runway. The implication is that the next leg of the turnaround can be funded from operating cash if working-capital normalisation does not reverse the gain.

Operating profitability is genuine even before the cash discussion. Operating profit swung to $7.7m from a $5.2m loss, on revenue up $18.3m. PBT growth of 147.4% and NPAT growth of 170.8% diverge by 23.4 percentage points, driven by an effective tax rate of -7.4% versus 28.1% in HY25, so PBT is the cleaner read on operating performance. ROE moved to 7.9% from -4.3%, although the smaller equity base flatters the ratio.

Expectations

No FY26 numerical target is supplied in the release, so the result has to be judged against shape rather than guidance

HY25 was 51.8% of FY25 revenue but only 6.2% of FY25 NPAT, because H2 FY25 absorbed a $98.3m implied loss tied to prior-period writedowns. That makes FY25 a poor anchor for full-year shape. Annualising HY26 revenue gives $235.9m, around 22.6% above FY25's $192.4m, but seasonality and channel timing in this business make that a directional reference only.

What the release supports is that H1 priorities were delivered: a return to profitability, positive operating cash flow, and debt reduction. What it does not support is a view on H2 earnings power, because the H2 outcome depends on whether revenue growth holds without the inventory tailwind.

Quality of result

The earnings recovery looks operationally durable: revenue grew 18.3%, operating profit swung by $12.9m, and the result was achieved on a smaller asset base

Receivable days actually improved to 51.4 from 56.6, so the revenue uplift is not being extended through customer credit.

The cash result is lower quality than the headline implies. Three items materially help reported cash:

  • Inventory release of $52.5m drove most of the $50.2m fall in operating working capital.
  • Capex of $0.5m versus $2.0m prior contributed $1.5m to FCF and is well below typical maintenance levels at 0.4% of revenue.
  • A negative effective tax rate (-7.4%) added to NPAT rather than subtracting from it, widening the gap between PBT and NPAT growth by 23.4 percentage points.

Once inventory normalises and capex returns to a maintenance run-rate, free cash flow would be expected to compress materially from the $16.4m reported here, even if operating profit holds.

Unresolved

Open questions

What is the steady-state inventory level the business is targeting, and how much of the $52.5m drawdown is structural versus cyclical destocking?
Why is the effective tax rate negative this half, and is a normal tax charge expected to resume in H2?
Is capex at 0.4% of revenue sustainable, or does the apiary and manufacturing base require a step-up in maintenance spend in FY27?
What drove the 18.3% revenue lift by region, and how much came from the China channel that was the prior-period drag?
How does management intend to use the $32.9m of debt headroom: further deleveraging, reinvestment, or capital return?

This briefing cannot assess underlying demand strength by region or channel, because segment revenue is not disclosed in the supplied financial statements.

Chat

Ask about CVT HY26

Ask follow-up questions about Comvita's HY26 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about CVT HY26

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Comvita's HY26 result.

What is the steady-state inventory level the business is targeting, and how much of the $52.5m drawdown is structural versus cyclical destocking?Why does "Cash conversion is overstated by working-capital release" matter?How strong was the cash and earnings quality in HY26?What should I watch next for CVT after HY26?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Comvita Delivers First-Half Priorities as Turnaround Continues

HY26 / results release↗

Financial Statements

HY26 / financial report↗

Investor Presentation

HY26 / results presentation↗

Results Announcement

HY26 / results announcement↗

Prior comparable period

Financial Statements

HY25 / financial report↗

Results Announcement

HY25 / results announcement↗

Results Announcement

HY25 / results release↗

Full-year context

Financial Statements

FY25 / financial report↗

Results Announcement

FY25 / results announcement↗

Results Announcement

FY25 / results release↗

Release context

Comvita advises results of resolutions at Annual Meeting

HY26 / commentary↗

Comvita provides FY26 Trading Update

HY26 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 23.4pp, with a distortion flag in the result.

→

Revenue growth context

Revenue growth was 18.3% for this reporting period.

→

ROE and capital efficiency

ROE was 7.9%, +12.2pp versus the prior comparable period.

→

Working-capital pressure

Inventory days were 105 days, -115 days versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when CVT publishes next

Get the next Comvita briefing and related NZX reporting-season updates by email.